Financhill
Sell
42

PTGX Quote, Financials, Valuation and Earnings

Last price:
$89.05
Seasonality move :
29.24%
Day range:
$87.47 - $89.47
52-week range:
$33.70 - $96.54
Dividend yield:
0%
P/E ratio:
140.11x
P/S ratio:
27.21x
P/B ratio:
8.59x
Volume:
329.1K
Avg. volume:
979.9K
1-year change:
126.06%
Market cap:
$5.5B
Revenue:
$434.4M
EPS (TTM):
$0.63

PTGX Analysts' Consensus Rating

The 9 analysts providing 12-month price projections for Protagonist Therapeutics, Inc. shares anticipate an average target of $94.50, ranging from a low estimate of $65.00 to a high estimate of $115.00. This average target implies a growth of 6.5% compared to the current stock price of $88.73.

Consensus Price Target

$94.50

Highest Price Target

$115.00

Lowest Price Target

$65.00

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Analyst Ratings

6M Ago 1M Ago Current
Buy 6 9 8

Hold 1 1 1

Sell 0 0 0
Consensus Buy Buy Buy

PTGX Recommendation Trends

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is DocuSign Stock Undervalued?
Is DocuSign Stock Undervalued?

Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…

Is SentinelOne Stock Undervalued?
Is SentinelOne Stock Undervalued?

Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…

Is Broadcom Stock on Sale?
Is Broadcom Stock on Sale?

Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…

Stock Ideas

Buy
59
Is NVDA Stock a Buy?

Market Cap: $4.6T
P/E Ratio: 64x

Buy
55
Is AAPL Stock a Buy?

Market Cap: $4T
P/E Ratio: 37x

Buy
61
Is GOOG Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 39x

Alerts

Buy
85
HUT alert for Dec 25

Hut 8 Corp. [HUT] is up 0.65% over the past day.

Buy
80
TVTX alert for Dec 25

Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.

Buy
63
GPCR alert for Dec 25

Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock